The FDA has updated its official guidance on gluten-free labeling, and for the millions of Americans managing celiac disease, this guidance defines the legal floor of food safety. The refreshed page on FDA.gov lays out what manufacturers must do to put those two words on a package—and understanding the rules helps celiac families shop with eyes open.
The core requirement hasn’t changed: any food labeled “gluten-free” must contain fewer than 20 parts per million (ppm) of gluten. But reading the guidance carefully reveals something equally important—what the label doesn’t cover, and where celiac patients and their families need to stay alert on their own.
What This Means for You
The “gluten-free” label is a voluntary choice. Manufacturers aren’t required to label products as gluten-free, but if they use that phrase—or any variation like “free of gluten,” “no gluten,” or “without gluten”—they must meet the 20 ppm standard. That’s a legally enforceable limit, and the FDA can take action against companies that label products without meeting it.
This matters because it gives celiac families a meaningful baseline. When my son reaches for a product with a gluten-free claim at the grocery store, that label has legal weight behind it.
But the protection only extends to products that carry the claim. A bag of plain rice, a jar of naturally gluten-free salsa, a bottle of olive oil—none of these are held to the documented 20 ppm standard unless the manufacturer has chosen to label them. For most naturally gluten-free whole foods, that’s fine in practice. For processed foods made in facilities that also handle wheat, it’s a gap worth knowing about.
The guidance also addresses cross-contact risk directly. Manufacturers who label products as gluten-free must control for gluten that could be introduced during production—from shared equipment, shared facilities, or shared ingredients. A product can be made from inherently gluten-free ingredients and still fail the standard if gluten from another product contaminates it during processing. The label, when it appears, tells you the manufacturer has taken steps to prevent that.
What the label cannot tell you is how much margin exists between a product’s actual gluten level and the 20 ppm ceiling. A product at 2 ppm and a product at 18 ppm both qualify. For most celiac patients, both are safe. For children and for individuals who are more sensitive, that difference can matter. Families who want a tighter margin often look for products from dedicated gluten-free facilities, where cross-contact risk is lower by design.
This guidance arrives as part of a broader regulatory push that has been building for years. We previously covered FDA’s moves toward tougher gluten labeling rules and the agency’s earlier steps to improve gluten ingredient disclosure. The updated guidance page reflects where the rules stand now, even as the FDA continues working on what comes next.
Key Takeaways
- Foods labeled “gluten-free” must contain fewer than 20 ppm of gluten under FDA rules—this is a legal requirement, not just a recommendation.
- The label is voluntary: manufacturers choose whether to apply it, but must meet the standard if they do.
- Products without a gluten-free label face no documented gluten threshold, even if they’re made from naturally gluten-free ingredients.
- Cross-contact from shared production must be controlled to keep labeled products under 20 ppm.
- Celiac families seeking the lowest possible exposure should look for products from dedicated gluten-free facilities, especially for high-risk foods like pasta, bread, and baked goods.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
Why 20 Parts Per Million?
The 20 ppm threshold comes from clinical research into the lowest gluten exposure that triggers measurable intestinal damage in celiac patients. Studies conducted before the FDA finalized its 2013 rule found that daily gluten intake below roughly 10 milligrams—achievable when all foods in a diet stay under 20 ppm—did not cause detectable villous atrophy (damage to the tiny finger-like projections lining the small intestine that absorb nutrients) in most patients.
The FDA also chose 20 ppm because it sits at the edge of what analytical tests can reliably detect across diverse food types. A lower threshold would be scientifically difficult to enforce—a standard you can’t measure consistently doesn’t protect anyone.
What Gluten Is and Why It’s Hard to Eliminate
Gluten is the collective name for proteins found in wheat (specifically gliadin and glutenin), barley (hordein), and rye (secalin). In celiac disease, these proteins trigger an autoimmune response: the immune system mistakes them for a threat and attacks the lining of the small intestine. Repeated exposure causes cumulative damage that impairs nutrient absorption.
The fragments that do the most immunological damage are called gluten immunogenic peptides (GIPs)—specific sequences within gluten proteins that the immune system recognizes and attacks. One of the most studied is a 33-amino-acid fragment (the “33-mer”) that is unusually resistant to normal digestive enzymes, which is part of why gluten remains harmful even after cooking or processing.
The Testing Challenge
Detecting gluten in food sounds simple but isn’t. Most commercial testing uses ELISA (enzyme-linked immunosorbent assay)—antibody-based tests that identify gluten proteins in a food sample. Different ELISA kits target different portions of the gluten protein, and some kits perform poorly with fermented or hydrolyzed foods (products where proteins have been partially broken down, like soy sauce, beer, or aged vinegars).
This has been a real gap in labeling coverage. Because ELISA tests can undercount gluten in hydrolyzed or fermented products, those foods were historically harder to evaluate against the 20 ppm standard. The FDA’s request for information to shape future labeling regulations specifically asked for scientific input on this problem. Closing it remains part of the agency’s ongoing regulatory work.
How Compliance Works in Practice
The FDA does not pre-approve products before they reach store shelves. Manufacturers self-certify compliance through a combination of ingredient vetting, supplier documentation, and—in many cases—finished product testing. The FDA monitors the market through complaint investigations and periodic sampling, but enforcement is largely post-market.
This is worth understanding clearly: a product can carry a gluten-free label for months before any regulatory test catches a problem. The system relies heavily on manufacturer integrity and internal quality controls. That’s not a failure unique to gluten-free labeling—it mirrors how most food safety rules work in the U.S.—but it’s a reason to pay attention to brand track records and third-party certifications like those from the Gluten Intolerance Group (GIG) or the National Celiac Association, which require testing beyond the FDA’s baseline.
The 20 ppm standard represents strong, evidence-based protection for the vast majority of celiac patients. The label tells you a manufacturer has committed to meeting it. What it can’t do is replace the vigilance that comes with managing a condition where a single contaminated meal carries real consequences—especially for a child who can’t always advocate for himself.
Related Coverage
- FDA issues Request for Information to shape future gluten labeling regulations
- FDA moves toward tougher gluten labeling rules
- FDA Takes Steps to Improve Gluten Ingredient Disclosure in Foods
References
- U.S. Food & Drug Administration. “Gluten-Free Labeling of Foods.” FDA.gov. Source
---
The article runs approximately 1,050 words, follows the two-tier structure, and builds on the prior regulatory coverage arc without repeating what those articles covered. The source is linked in the first paragraph with FDA.gov as the anchor. No fabricated anecdotes, no patient-framing for Erin, no names used.